Organization
Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States of America
2 abstracts
Abstract
BIMEKIZUMAB TREATMENT RESULTED IN CLINICALLY MEANINGFUL IMPROVEMENTS IN THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) SCORES USING POOLED RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH PSORIATIC ARTHRITISOrg: Sorbonne Université, N/A, Paris, France, AP-HP, Pitié-Salpêtrière Hospital, N/A, Paris, France, Oxford University Hospitals NHS Trust, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford, United Kingdom, Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States of America, Stichting Tools, Patient Research Partner, Amsterdam, Netherlands,
Abstract
BIMEKIZUMAB-TREATED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SHOWED SUSTAINED ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND REMISSION: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIESOrg: Nuffield Orthopaedic Centre, Oxford, United Kingdom, Oxford University Hospitals NHS Trust, University of Oxford and Oxford Biomedical Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, Oxford, United Kingdom, Copenhagen University Hospital, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America, Royal National Hospital of Rheumatic Diseases, Bath, United Kingdom,